Breaking the Stigma with Advancements in Psychedelics
In this episode of Breakthrough Economy, MindMed CEO Robert Barrow chats with Host Jen Rogers about how his company, which was the first psychedelic pharmaceutical company to go public, is working to unlock the full therapeutic potential of psychedelics and other novel therapeutic targets.
Women in Science: Cynthia Pussinen, CEO of Sernova on how her career was ‘written in the stars’
Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.
Everybody Has a Thyroid… What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma
Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.
Overviewing Preliminary Data of ABvac40, a Vaccine for Alzheimer Disease: Jose Terencio
The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease.
Navigating the challenges of cell therapies
Vittoria’s innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of cell therapies.
The Legend Steve Gorlin’s Golden Rules
This week, the Business of Biotech sits down with the legendary biotech investor Steve Gorlin, now CEO of CoRegen, for a conversation on his golden rules for picking winners.
Locks on Translation Initiation May Restrain Cancer
Effector Therapeutics is working on selective translation regulator inhibitors (STRIs).
Can gene editing drive out HIV and hepatitis viruses from inside cells?
GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection